ClinicalTrials.gg
RecruitingNCT07527741Close2HERUpdated Nov 6, 2026

A Study to Assess Treatment Patterns and Treatment Adherence in Early HER2-positive Breast Cancer Participants After Treatment Decentralization

An observational study in Early-stage HER2+ Breast Cancer, sponsored by Hoffmann-La Roche. Recruiting at 10 sites in Serbia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Hoffmann-La Roche · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 8, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 229 studies in Breast Neoplasms by Hoffmann-La Roche — 16 open to participants now, 27 under way, 13 of them phase 3. Breast Neoplasms · Hoffmann-La Roche.

Planned enrollment
38th of 49
100 · median 276
Started
2026
with 9 others
Observational
49 of 229
2 open now
Primary completion
2028-10
later than 15 of 26 live
Registered
224th of 229
by date

Among the 229 studies in Breast Neoplasms by Hoffmann-La Roche, this one is the 38th largest by planned enrollment of the 49 observational ones that give a count, is one of 10 that started in 2026, is one of 49 observational ones, reaches primary completion later than 15 of the 26 other live ones, and was the 224th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

16 of the 229 studies in Breast Neoplasms by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 229 studies in Breast Neoplasms by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the impact of a decentralized treatment model on treatment adherence in participants with early-stage human epidermal growth factor receptor 2- positive (HER2+) breast cancer (BC).

This study has 2 groups: Group 1: Consistent Travel Burden (Cohorts A, C, and D), will include participants whose adjuvant therapy location does not increase their travel requirements, and Group 2: Increased Travel Burden (Cohort B), will include participants who must travel from a secondary center to a tertiary center to receive their adjuvant therapy.

03

Conditions studied

  • Early-stage HER2+ Breast Cancer

Browse trials for

Keywords

  • Decentralization
  • Anti-HER2 therapy
  • Real-world data
  • Early-stage HER2+ BC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of participants diagnosed with HER2-positive eBC who are initiating or undergoing treatment following a nationwide healthcare policy change in Serbia that decentralized the administration of anti-HER2 therapies.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of stage II and III + eBC according to European Society For Medical Oncology (ESMO) guidelines
  • Underwent curative-intent surgical resection for BC
  • documented HER2-positive BC (determined per American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] guidelines) before or after surgery

Exclusion criteria

Exclusion Criteria:

  • Any medical or psychiatric condition that, in the investigator's opinion, would compromise the participant's ability to provide or to complete study-related questionnaires
  • Receipt of prior or adjuvant therapy for + BC at a center other than the 10 participating study sites (Bor, Kladovo, Institute for oncology and Radiology of Serbia (IORS), Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, Valjevo)
  • Participants administratively belonging to the following secondary centers: Bor, Kladovo, Loznica, Pančevo, Požarevac, Smederevo, Smederevska Palanka, Šabac, or Valjevo, who initiated neoadjuvant therapy at IORS instead of their local secondary center
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Cohort A

    Participants who received neoadjuvant therapy and achieved pathological complete response (pCR) and receive their adjuvant treatment at a designated secondary or tertiary center, administratively assigned based on their place of residence will be observed to assess the impact on quality of life (QoL) and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions.

  • Group 2: Cohort B

    Participants who received neoadjuvant therapy at a secondary center and were subsequently found to have residual invasive disease will be referred to a centralized referent tertiary institution to receive their adjuvant treatment and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions.

  • Group 1: Cohort C

    Participants who received neoadjuvant therapy at their designated tertiary center, which is the institution administratively assigned based on their place of residence, and subsequently found to have residual invasive disease will continue with adjuvant treatment at the same institution, and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions.

  • Group 1: Cohort D

    Participants who missed neoadjuvant therapy and underwent primary BC surgery will start adjuvant treatment at their designated secondary hospital or tertiary center, which is the institution administratively assigned based on their place of residence and will be observed to assess the impact on QoL and travel burden. All treatment decisions will be made at the discretion of the treating physician and participant, reflecting routine clinical practice without any study-mandated interventions.

06

What researchers measure

Primary outcomes

  1. Treatment Adherence Rate

    Time frame: Up to 2.25 years

Secondary outcomes

  1. Treatment Completion Rate for Anti-HER2 Treatment

    Time frame: Up to 2.25 years

  2. Percentage of Participants With ≥1 Dose Delays Exceeding a Pre-defined Threshold (3 Weeks) From the Scheduled Date

    Time frame: Up to 2.25 years

  3. Mean Travel Burden Between Group 1 (Cohorts A, C, D) and Group 2 (Cohort B) During the Adjuvant Therapy Phase

    Travel Burden is a composite measure encompassing both objective and subjective components. Objective travel burden is defined by the one-way travel distance (in kilometers \[km\]) and one-way travel time (in minutes) from the participant's residence to the treatment center. Subjective travel burden will capture the participant's personal experience and will be assessed using patient-reported outcomes collected via dedicated questionnaires.

    Time frame: Up to 2.25 years

  4. Cohort B: Change in Intra-participant Travel Burden Between the Neoadjuvant and Adjuvant Treatment Centers

    Travel Burden is a composite measure encompassing both objective and subjective metrices. Objective travel metrics include driving distance and travel time and subjective, patient-reported metrics include out-of-pocket costs, mode of transport, and perceived travel-related challenges. Intra-participant travel burden between the Neoadjuvant and Adjuvant treatment centers will be done as a longitudinal analysis of the change in these metrics from the neoadjuvant to the adjuvant phase.

    Time frame: Up to 2.25 years

  5. Difference in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/QoL Score, Between Participants of Cohort B and Cohort C

    EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, \& social), 3 symptom scales (fatigue, nausea \& vomiting, \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better health-related quality of life (HRQoL).

    Time frame: At 6 months post-baseline

  6. Mean Intra-patient Change in the EORTC QLQ-C30 GHS/QoL Score

    EORTC QLQ-C30 is a cancer-specific instrument consisting of 30 questions that evaluates 5 aspects of participant functioning (physical, emotional, role, cognitive, \& social), 3 symptom scales (fatigue, nausea \& vomiting, \& pain), GHS/QoL \& 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea \& financial difficulties). The GHS/QoL questions will be scored on a 7-point scale, with scores ranging from 1=Very poor to 7=Excellent. Scores will be linearly transformed to a range of 0-100. A high score for a GHS/QoL scale indicates a better HRQoL.

    Time frame: Cohorts A, B and C: Baseline to Month 6; Cohort D: Month 6 to Month 12

  7. Time to Neoadjuvant Treatment Initiation

    Time to Neoadjuvant Treatment Initiation was defined as time from early breast cancer (eBC) diagnosis to the start of neoadjuvant treatment. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

    Time frame: At Baseline

  8. Time to Surgery

    Time to surgery was defined as the time from the neoadjuvant treatment completion to surgery. Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

    Time frame: At Baseline

  9. Time to Adjuvant Treatment Initiation

    Time frame: Time from surgery to the start of adjuvant treatment (up to approximately 1.25 years)

  10. Percentage of Participants Treated at Least Once With Neoadjuvant Therapy

    Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

    Time frame: At Baseline

  11. Percentage of Participants Not Treated With Neoadjuvant Therapy

    Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

    Time frame: At Baseline

  12. Percentage of Participants With pCR After Neoadjuvant Systemic Therapy Completion

    Data for neoadjuvant treatment will be collected retrospectively at the baseline visit using the participant's medical records.

    Time frame: At Baseline

07

Study locations

10 of 10 sites recruiting
  • Health Centre Loznica
    Loznica, Bolnička 65 15300, Serbia
    Recruiting
  • General Hospital Požarevac
    Požarevac, Bratstva Jedinstva 135 12000, Serbia
    Recruiting
  • Healthcare Centre Bor
    Bor, Dragiše Mišovića 1 19210, Serbia
    Recruiting
  • Health Centre Kladovo
    Kladovo, Dunavska 1-3 19320, Serbia
    Recruiting
  • Health Centre ''Sveti Luka'' Smederevo
    Smederevo, Knez Mihailova 51 11300, Serbia
    Recruiting
  • General Hospital Pančevo
    Pančevo, Miloša Trebinjca 11 26000, Serbia
    Recruiting
  • Institute for Onocology and Radiology of Serbia
    Belgrade, Pasterova 14 11000, Serbia
    Recruiting
  • General Hospital "Dr Laza K. Lazarevic" Sabac
    Šabac, Popa Karana 2-4 15000, Serbia
    Recruiting
  • Health Centre Valjevo
    Valjevo, Sinđelićeva 62 14000, Serbia
    Recruiting
  • General Hospital ''Stefan Visoki'' Smederevska Palanka
    Smederevska Palanka, Vuka Karadžića 147 11420, Serbia
    Recruiting
08

References and documents

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Oct 2028, 32 months after the start.

Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 32 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion May 2028 → Oct 2028 and completion May 2028 → Oct 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 14, 2026
StartActual
Feb 23, 2026
Primary completionEst.
Oct 31, 2028was May 2028
CompletionEst.
Oct 31, 2028was May 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 31, 2028→Oct 31, 2028
Oct 8, 2026
Study completion
May 31, 2028→Oct 31, 2028
Oct 8, 2026
Show all 3 updates
  1. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 8, 2026
    Primary completion May 31, 2028→Oct 31, 2028
    Study completion May 31, 2028→Oct 31, 2028
  3. Oct 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07527741
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Feb 23, 2026
Primary completion
Oct 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Reference Study ID Number: ML46477 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion